A potency assay measures a product's ability to produce a defined biological effect. For peptides and biologics, the assay may evaluate receptor activation, second-messenger signaling, cell proliferation, inhibition, cytotoxicity, or another mechanism-linked response.
Potency is not the same as mass, purity, or clinical effectiveness. It is biological activity relative to a method and usually to a reference standard.
The assay should connect to mechanism
A useful potency assay reflects a biological property relevant to the product's intended activity. The connection can be direct, such as receptor-mediated signaling, or supported by a chain of evidence linking a measurable response to the mechanism of action.
Complex products may have more than one relevant mechanism. One assay may not capture every function. A matrix of complementary assays can be appropriate when no single readout represents the total activity.
The report should explain why the selected response is meaningful rather than choosing a convenient cell signal without context.
Relative potency compares dose-response curves
In many bioassays, serial dilutions of test and reference material produce sigmoidal response curves. Relative potency estimates how far one curve is shifted along the concentration axis when their shapes are sufficiently similar.
If test and reference curves are parallel under the model, a horizontal shift can be interpreted as a concentration or potency ratio. If slopes or asymptotes differ substantially, a single relative-potency number may not be meaningful because the materials do not behave as diluted versions of each other.
Parallelism and model fit are therefore central acceptance criteria, not cosmetic statistics.
Four-parameter logistic models are common
A four-parameter logistic curve estimates lower asymptote, upper asymptote, slope, and midpoint. A five-parameter model adds asymmetry. Extra flexibility can improve fit but also make potency comparison unstable.
The validated model, weighting, response transformation, and acceptance criteria should be prespecified. The tested concentration range must cover enough of both curves to estimate their shapes; fitting only one flat region produces an unreliable midpoint.
Raw response plots should accompany the final percentage.
The reference standard defines the unit
Relative potency is anchored to a qualified reference lot with an assigned activity. If that standard drifts, degrades, or is replaced without bridging, reported potency can shift even when test lots do not.
Reference qualification includes identity, stability, storage, reconstitution, and enough inventory or a replacement strategy. An international or compendial standard may define units for some products, while an in-house standard supports product-specific comparability.
“120% relative potency” generally means that the estimated activity per stated amount is 1.2 times that of the reference under the assay. It does not mean 120% pure or 20% clinically better.
Cells are variable reagents
Cell passage, receptor expression, confluence, viability, serum lot, culture time, thaw history, and incubator conditions can change response. Reporter-gene systems can drift through selection pressure or genetic instability.
Controls should monitor maximum and minimum response, reference curve behavior, cell health, and plate effects. Cell-bank strategy and passage limits belong in the control system.
Automation can improve timing and precision but does not remove biological variability.
Sample matrix can change apparent activity
Formulation components, residual solvents, pH, osmolality, or cytotoxic impurities can alter the cell response independently of the target mechanism. Dilution often reduces matrix effects, but it can also move the analyte outside the informative range.
Spiking, dilutional parallelism, and matrix-matched controls can distinguish true potency from nonspecific enhancement or inhibition. A viability counter-assay is useful when reduced signaling could reflect cell death.
Precision is built across runs
Bioassays typically have greater variability than physicochemical assays. Validation evaluates repeatability, intermediate precision across analysts and days, accuracy or relative bias, range, specificity, and robustness.
Replicates within one plate capture only part of the uncertainty. Independent runs are needed for a reportable lot result. The aggregation rule, geometric mean, weighted estimate, or another approach, should be predefined.
Confidence intervals communicate the precision of relative potency better than a lone percentage.
System suitability protects each run
Typical criteria can address:
- reference curve parameter ranges;
- signal window;
- model fit;
- slope or parallelism;
- control responses;
- replicate variability;
- plate position effects;
- test-sample curve coverage.
Failure should trigger investigation under predefined rules. Repeating until a passing result appears creates selection bias.
A report checklist
Look for:
- biological mechanism and cell or system identity;
- reference standard and assigned activity;
- sample preparation and dilution series;
- response endpoint and timing;
- curve model and weighting;
- parallelism and fit criteria;
- system-suitability results;
- independent run count;
- relative potency with confidence interval;
- specification, invalid-run rules, and deviations.
What potency does not prove
A passing bioassay does not independently establish identity, purity, content, sterility, endotoxin, or clinical benefit. An impurity can be biologically active in the same assay, and an intact target can lose activity through conformation or formulation changes.
Physicochemical and biological assays answer complementary questions.
Bottom line
A potency result is a controlled comparison between test and reference dose-response behavior. Its credibility depends on mechanistic relevance, curve similarity, reference stability, cell controls, and run-to-run precision. Read the curve and its uncertainty, not only the final percent.
Sources
- United States Pharmacopeia. General Chapter <1032> Design and Development of Biological Assays.
- United States Pharmacopeia. General Chapter <1033> Biological Assay Validation.
- United States Pharmacopeia. General Chapter <1034> Analysis of Biological Assays.
- International Council for Harmonisation. Q6B: Specifications, Biotechnological/Biological Products.
- U.S. Food and Drug Administration. Q6B Specifications for Biotechnological/Biological Products.
Continue reading
Editorial responsibility and corrections
Published by Serum Research. Sources checked October 1, 2026. This is educational material; no independent scientific, clinical, statistical, analytical, or regulatory review is claimed. Read how we review evidence or send a correction.
For Research Use Only. Not for Human Consumption. This page does not provide instructions for medical use or establish the identity, quality, safety, or equivalence of a catalog material.